Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2 (IL-2, Proleukin) and immune function

    Project Inform Perspective
    |March 22, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Interleukin-2 (IL-2) therapy significantly boosts CD4+ cell counts in patients undergoing anti-HIV treatment. This immune-based approach shows promise for enhancing HIV therapy outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles

    Area of Science:

    • Immunology
    • Virology
    • Pharmacology

    Background:

    • Interleukin-2 (IL-2) is an immune-based therapy.
    • IL-2 therapy, in combination with anti-HIV treatments, demonstrates significant increases in CD4+ cell counts.
    • Previous discussions of IL-2 in PI Perspective necessitate an updated review due to new information.

    Discussion:

    • The synergistic effect of IL-2 with anti-HIV therapy on CD4+ T-cell restoration is a key area of focus.
    • Understanding the mechanisms behind IL-2's efficacy in boosting CD4+ counts is crucial for optimizing HIV treatment strategies.
    • Evaluating the safety and long-term benefits of IL-2 as an adjunct therapy for HIV warrants further investigation.

    Key Insights:

    • IL-2 therapy leads to dramatic increases in CD4+ cell counts.

    Related Experiment Videos

  • The combination of IL-2 and anti-HIV therapy offers a potent strategy for immune reconstitution.
  • New data supports a renewed examination of IL-2's role in HIV management.

    • Outlook:

    • Further clinical trials are needed to establish optimal IL-2 dosing and treatment protocols for HIV patients.
    • Investigating the impact of IL-2 on viral load suppression and overall patient prognosis is essential.
    • Exploring potential applications of IL-2 in other immune-compromising conditions may arise from these findings.